Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Arovella Therapeutics Limited ( (AU:ALA) ) has issued an update.
Arovella Therapeutics has received a purported shareholder notice under section 249D of the Corporations Act from The Trust Company (Australia) Limited SBF A/C, which holds more than 5% of its voting shares. The notice requests a general meeting where investors would vote on appointing David Williams, Mark Diamond and Michael Thurn as directors, conditional on at least one board seat becoming vacant.
The company is currently assessing the validity of the notice and the conditional resolutions, noting that if deemed valid, directors must call a general meeting within 21 days and hold it within two months. Arovella also clarified that, despite references in the notice, it has not received any formal resolutions to remove existing directors or any accompanying members’ statement, signalling potential governance tensions but no confirmed board changes yet.
The most recent analyst rating on (AU:ALA) stock is a Sell with a A$0.06 price target. To see the full list of analyst forecasts on Arovella Therapeutics Limited stock, see the AU:ALA Stock Forecast page.
More about Arovella Therapeutics Limited
Arovella Therapeutics Limited is an Australian biotechnology company focused on developing its invariant Natural Killer T (iNKT) cell therapy platform. The company targets advanced cell-based immunotherapies, positioning itself within the emerging oncology and cell therapy market.
Average Trading Volume: 952,760
Technical Sentiment Signal: Sell
Current Market Cap: A$84.5M
Learn more about ALA stock on TipRanks’ Stock Analysis page.